Foghorn Therapeutics Inc. (FHTX) Free cash flow 2019–2025
Foghorn Therapeutics Inc. (FHTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$86.1MFY2025 · since FY2019: -$47.3M → -$86.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$86.1M | +15.0% |
| FY2024 | -$101.3M | +15.1% |
| FY2023 | -$119.3M | -162.0% |
| FY2022 | $192.4M | +459.2% |
| FY2021 | -$53.6M | -12.8% |
| FY2020 | -$47.5M | -0.4% |
| FY2019 | -$47.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More FHTX financial trends
FHTX RevenueFHTX Net incomeFHTX Net marginFHTX Gross profitFHTX Gross marginFHTX Operating incomeFHTX Operating marginFHTX Operating cash flowFHTX Capital expendituresFHTX Return on equityFHTX Stock buybacksFHTX Dividends paidFHTX Total assetsFHTX Total liabilitiesFHTX Shareholders’ equityFHTX overview →